Breast Enlargement and Epicardial Fat Deposits
Triglyceride buildup in cytoplasmic vesicles in the liver cells is the pathological basis for hepatic steatosis, often known as fatty liver disease. Gynecomastia is the abnormal and usually benign enlargement of male breast tissue. The psychological and emotional toll of dealing with the physical manifestations of gynecomastia may be significant to most male patients. Gynecomastia is often diagnosed when the size of the affected glands exceeds 2 centimeters in the subareolar region. Between 32 and 65 percent of men have gynecomastia, and 44 percent of cirrhotic individuals due to NAFLD have it.
There is evidence from some research that hepatic liver dysfunction contributes to the development of gynecomastia. Lane’s disease, testicular shrinkage, and gynecomastia are all symptoms of low testosterone and high estrogen levels, which are common in patients with hepatic steatosis.
Meanwhile, epicardial fat thickness, a measure of visceral fat, has been linked to hepatic steatosis severity. Epicardial fat may coexist with hepatic steatosis and interact with it. Epicardial fat covers 80 percent of the heart’s surface. Despite being mostly ignored, past research has shown a correlation between epicardial fat thickness and several illnesses, including NAFLD. It reliably predicts hepatic steatosis in obese people and is correlated with disease severity in NAFLD patients.
